Aisen, P;
Touchon, J;
Amariglio, R;
Andrieu, S;
Bateman, R;
Breitner, J;
Donohue, M;
... Vanessa, Z; + view all
(2017)
EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.
The Journal of Prevention of Alzheimer's Disease
, 4
(2)
pp. 116-124.
10.14283/jpad.2017.13.
Preview |
Text
2017 JPAD EUUSCTAD task force lessons from prevention studies - author ms.pdf - Accepted Version Download (344kB) | Preview |
Abstract
At a meeting of the EU/US/Clinical Trials in Alzheimer’s Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned from ongoing and planned prevention trials, which will help guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force discussed challenges that need to be addressed across all aspects of clinical trials, calling for innovation in recruitment and retention, infrastructure development, and the selection of outcome measures. While cognitive change provides a marker of disease progression across the disease continuum, there remains a need to identify the optimal assessment tools that provide clinically meaningful endpoints. Patient- and informant-reported assessments of cognition and function may be useful but present additional challenges. Imaging and other biomarkers are also essential to maximize the efficiency of and the information learned from clinical trials.
| Type: | Article |
|---|---|
| Title: | EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.14283/jpad.2017.13 |
| Publisher version: | https://doi.org/10.14283/jpad.2017.13 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Alzheimer’s disease; clinical trials; secondary prevention trials; cognitive outcome measures; cognitive composites; patient-reported outcome measures; informant-reported outcome measures; molecular imaging; mild behavioral impairment |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10078031 |
Archive Staff Only
 |
View Item |
